Janssen Pharmaceuticals, Inc (2019) Invokana (canagliflozin) tablets
Both matter for choosing between oral and injectable forms
Key takeaways Retatrutide isn't approved yet and isn't expected to launch in the UK until at least mid-2026 In clinical trials, target doses ranged from 0.5mg to 12mg weekly, with the most common being 4mg, 8mg, 9mg and 12mg Different dosing schedules were tested, with most people starting at 2mg and escalating every 4 weeks The 12mg dose produced the most weight loss (up to 28.7% after 68 weeks) Starting at 2mg rather than 4mg helped reduce side effects during escalation First to know Get an email the day retatrutide launches in the UK
The discussion will address the following questions: 1
Optional Microbiome Support For individuals seeking additional support during metabolic repair, microbiome-targeted formulations may help complement diet and lifestyle
For others, a scheduled visit every few weeks is far easier than remembering anything daily